Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Thomas Cohn

Interventional Pain Medicine Sartell, MN Medical Doctor

NPI 1245273390 CMS profile 101462

166 19Th Street South, Suite 100, Sartell, MN 56377

Open in the dashboard

General payments

$619

14 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Thomas Cohn of Sartell, MN is reported in the CMS Open Payments database as having received $619 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 19th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $78 3
2019 General $541 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Cohn
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Thomas Cohn were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Thomas Cohn Interventional Pain Medicine median Middle half National median
2019 $541 $684 $216–$2,079 $163
2020 $78 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Abbott Laboratories $396 6 payments
  2. Medtronic USA, Inc. $211 7 payments
  3. Stimwave Technologies Incorporated $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $619 14 payments
Products named General payments · program years 2019–2020
  1. Proclaim Family of SCS IPGs $282 3 payments
  2. INTELLIS $193 5 payments
  3. Octrode SCS Leads $102 2 payments
  4. Axium INS DRG IPG $12 1 payment
  5. ADAPTIVESTIM $10 1 payment
  6. RESTORE $8 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

221

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$7,279

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

12.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 100 $4,553
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $919
Tizanidine Hcl Generic 25 $827
Duloxetine Hcl Generic 15 $337
Oxycodone Hcl Generic 19 $288
Nortriptyline Hcl Generic 12 $228
Tramadol Hcl Generic 22 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$32,799

Of which drugs: $2,385

Medicare patients

141

Average age 71

Services billed

7,495

86 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 39%
Ischemic heart disease 30%
Diabetes 26%
Osteoporosis 19%
Atrial fibrillation 17%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 69 4,450 $1,282
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 20 59 $325
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 51 670 $60

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record